GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Avalon Globocare Corp (NAS:ALBT) » Definitions » Cash Flow from Financing

Avalon Globocare (Avalon Globocare) Cash Flow from Financing : $4.83 Mil (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Avalon Globocare Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, Avalon Globocare paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.37 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.37 Mil on other financial activities. In all, Avalon Globocare earned $0.73 Mil on financial activities for the three months ended in Dec. 2023.


Avalon Globocare Cash Flow from Financing Historical Data

The historical data trend for Avalon Globocare's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalon Globocare Cash Flow from Financing Chart

Avalon Globocare Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.16 7.66 5.17 17.26 4.83

Avalon Globocare Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.00 0.75 2.30 1.05 0.73

Avalon Globocare Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Avalon Globocare's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Avalon Globocare's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.83 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avalon Globocare  (NAS:ALBT) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Avalon Globocare's issuance of stock for the three months ended in Dec. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Avalon Globocare's repurchase of stock for the three months ended in Dec. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Avalon Globocare's net issuance of debt for the three months ended in Dec. 2023 was $0.37 Mil. Avalon Globocare received $0.37 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Avalon Globocare's net issuance of preferred for the three months ended in Dec. 2023 was $0.00 Mil. Avalon Globocare paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Avalon Globocare's cash flow for dividends for the three months ended in Dec. 2023 was $0.00 Mil. Avalon Globocare received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Avalon Globocare's other financing for the three months ended in Dec. 2023 was $0.37 Mil. Avalon Globocare received $0.37 Mil on other financial activities.


Avalon Globocare Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Avalon Globocare's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Avalon Globocare (Avalon Globocare) Business Description

Traded in Other Exchanges
N/A
Address
4400 Route 9 South, Suite 3100, Freehold, NJ, USA, 07728
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. It has two reportable segments: the real property operating segment which is the key revenue driver; medical-related consulting services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
Executives
Lourdes Felix director 15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
W J Tauzin director 901 HUGH WALLIS ROAD S, LAFAYETTE LA 70508
Wenzhao Lu director, 10 percent owner C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Andrew Sanders director 431 EAST 20TH STREET, NEW YORK NY 10010
Yancen Lu director 14009 SE 50TH STREET, BELLEVUE WA 98006
Stilley William B. Iii director 1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE VA 22901
Tevi Troy director 611 SOMERSWORTH WAY, SILVER SPRING MD 20902
Luisa Ingargiola officer: Chief Financial Officer 4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
David Jin director, officer: CEO and President C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Yue Charles Li director C/O AVALON GLOBOCARE CORP., 4400 ROUTE 9 SOUTH, SUITE 3100, FREEHOLD NJ 07728
Meng Li director, officer: Chief Operating Officer C/O GLOBAL TECHNOLOGIES CORP., 3 SOUTH STREET, SUITE 101, FREEHOLD NJ 97728
Steven Philip Sukel director 33 ALPINE DRIVE, MORGANVILLE NJ 07751

Avalon Globocare (Avalon Globocare) Headlines